Publications by authors named "Mary Hengen"

Article Synopsis
  • The CIBMTR's 2023 summary slides now include data on CAR-T therapy and patient-reported outcomes (PROs), enhancing the understanding of transplantation trends.
  • The CIBMTR launched a PRO data collection protocol in August 2020 to gather insights from adult hematopoietic cell transplantation (HCT) and CAR-T recipients at participating centers.
  • As of September 2023, PRO data from 993 patients across 25 centers have been collected and integrated with clinical data to improve patient care and support comprehensive research.
View Article and Find Full Text PDF

Implementation science (IS) is a systematic way to approach the broader adoption of evidence-based practices and has as its goal to understand and address the gap between research and practice, ensuring that research findings are effectively translated into practice and policy to improve health outcomes and service. We describe the various facets of IS and their relevance to the field of hematopoietic cell transplantation and cellular therapy (HCT/CT) with an emphasis on health equity, community engagement, and systems approach. We also review the similarities and differences among clinical research, quality improvement, and IS.

View Article and Find Full Text PDF

The use of HLA-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United States. However, real-world trends and outcomes following mismatched donor HCT for diverse patients remain largely undefined. We conducted this study to determine whether the use of mismatched donor platforms have increased the access to allogeneic HCT for ethnically diverse patients, particularly through the application of novel graft-versus-host disease (GVHD) prophylaxis regimens, and whether outcomes for diverse patients are comparable to those of non-Hispanic White patients.

View Article and Find Full Text PDF

Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States.

View Article and Find Full Text PDF